Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

por Cooper, Zachary A., Frederick, Dennie T., Ahmed, Zain, Wargo, Jennifer A.
Publicado 2013

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

por Cooper, Zachary A, Reuben, Alexandre, Amaria, Rodabe N, Wargo, Jennifer A
Publicado 2014

Update on use of aldesleukin for treatment of high-risk metastatic melanoma

por Amaria, Rodabe N, Reuben, Alexandre, Cooper, Zachary A, Wargo, Jennifer A
Publicado 2015

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma

por Reuben, Alexandre, Amaria, Rodabe N, Cooper, Zachary A, Wargo, Jennifer A
Publicado 2014

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

por Kim, Teresa, Amaria, Rodabe N., Spencer, Christine, Reuben, Alexandre, Cooper, Zachary A., Wargo, Jennifer A.
Publicado 2014

EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells

por Wang, Haijuan, Gambosova, Katarina, Cooper, Zachary A, Holloway, Michael P, Kassai, Andrea, Izquierdo, Denisse, Cleveland, Kelly, Boney, Charlotte M, Altura, Rachel A
Publicado 2010

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

por Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Publicado 2013

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma

por Reuben, Alexandre, Cooper, Zachary A, Amaria, Rodabe N, Forget, Marie A, Haymaker, Cara, Bernatchez, Chantale, Chen, Pei-ling, Tetzlaff, Michael T, Chin, Lynda, Dwyer, Karen C, Wargo, Jennifer A
Publicado 2014

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

por Sabbatino, Francesco, Wang, Yangyang, Wang, Xinhui, Flaherty, Keith T., Yu, Ling, Pepin, David, Scognamiglio, Giosue', Pepe, Stefano, Kirkwood, John M., Cooper, Zachary A., Frederick, Dennie T., Wargo, Jennifer A., Ferrone, Soldano, Ferrone, Cristina R.
Publicado 2014

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

por Smith, Michael P., Brunton, Holly, Rowling, Emily J., Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L., Girotti, Maria R., Marais, Richard, Levesque, Mitchell P., Dummer, Reinhard, Frederick, Dennie T., Flaherty, Keith T., Cooper, Zachary A., Wargo, Jennifer A., Wellbrock, Claudia
Publicado 2016

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

por Friedman, Adam A., Amzallag, Arnaud, Pruteanu-Malinici, Iulian, Baniya, Subash, Cooper, Zachary A., Piris, Adriano, Hargreaves, Leeza, Igras, Vivien, Frederick, Dennie T., Lawrence, Donald P., Haber, Daniel A., Flaherty, Keith T., Wargo, Jennifer A., Ramaswamy, Sridhar, Benes, Cyril H., Fisher, David E.
Publicado 2015

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

por Young, Helen L., Rowling, Emily J., Bugatti, Mattia, Giurisato, Emanuele, Luheshi, Nadia, Arozarena, Imanol, Acosta, Juan-Carlos, Kamarashev, Jivko, Frederick, Dennie T., Cooper, Zachary A., Reuben, Alexandre, Gil, Jesus, Flaherty, Keith T., Wargo, Jennifer A., Vermi, William, Smith, Michael P., Wellbrock, Claudia, Hurlstone, Adam
Publicado 2017

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

por Siu, Lillian, Brody, Joshua, Gupta, Shilpa, Marabelle, Aurélien, Jimeno, Antonio, Munster, Pamela, Grilley-Olson, Juneko, Rook, Alain H, Hollebecque, Antoine, Wong, Rebecca K S, Welsh, James W, Wu, Yuling, Morehouse, Christopher, Hamid, Oday, Walcott, Farzana, Cooper, Zachary A, Kumar, Rakesh, Ferté, Charles, Hong, David S
Publicado 2020

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

por Tu, Eric, McGlinchey, Kelly, Wang, Jixin, Martin, Philip, Ching, Steven L.K., Floc’h, Nicolas, Kurasawa, James, Starrett, Jacqueline H., Lazdun, Yelena, Wetzel, Leslie, Nuttall, Barrett, Ng, Felicia S.L., Coffman, Karen T., Smith, Paul D., Politi, Katerina, Cooper, Zachary A., Streicher, Katie
Publicado 2022

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

por Frederick, Dennie T., Salas Fragomeni, Roberto A., Schalck, Aislyn, Ferreiro-Neira, Isabel, Hoff, Taylor, Cooper, Zachary A., Haq, Rizwan, Panka, David J., Kwong, Lawrence N., Davies, Michael A., Cusack, James C., Flaherty, Keith T., Fisher, David E., Mier, James W., Wargo, Jennifer A., Sullivan, Ryan J.
Publicado 2014

Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

por Straussman, Ravid, Morikawa, Teppei, Shee, Kevin, Barzily-Rokni, Michal, Qian, Zhi Rong, Du, Jinyan, Davis, Ashli, Mongare, Margaret M., Gould, Joshua, Frederick, Dennie T., Cooper, Zachary A., Chapman, Paul B., Solit, David B., Ribas, Antoni, Lo, Roger S., Flaherty, Keith T., Ogino, Shuji, Wargo, Jennifer A., Golub, Todd R.
Publicado 2012

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

por Kim, Hyungsoo, Frederick, Dennie T., Levesque, Mitchell P., Cooper, Zachary A., Feng, Yongmei, Krepler, Clemens, Brill, Laurence, Samuels, Yardena, Hayward, Nicholas K., Perlina, Ally, Piris, Adriano, Zhang, Tongwu, Halaban, Ruth, Herlyn, Meenhard M., Brown, Kevin M., Wargo, Jennifer A., Dummer, Reinhard, Flaherty, Keith T., Ronai, Ze’ev A.
Publicado 2015

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

por Smith, Michael P, Rowling, Emily J, Miskolczi, Zsofia, Ferguson, Jennifer, Spoerri, Loredana, Haass, Nikolas K, Sloss, Olivia, McEntegart, Sophie, Arozarena, Imanol, von Kriegsheim, Alex, Rodriguez, Javier, Brunton, Holly, Kmarashev, Jivko, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Andrews, Miles C, Cooper, Zachary A, Flaherty, Keith T, Wargo, Jennifer A, Wellbrock, Claudia
Publicado 2017

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

por Bendell, Johanna, LoRusso, Patricia, Overman, Michael, Noonan, Anne M., Kim, Dong-Wan, Strickler, John H., Kim, Sang-We, Clarke, Stephen, George, Thomas J., Grimison, Peter S., Barve, Minal, Amin, Manik, Desai, Jayesh, Wise-Draper, Trisha, Eck, Steven, Jiang, Yu, Khan, Anis A., Wu, Yuling, Martin, Philip, Cooper, Zachary A., Elgeioushi, Nairouz, Mueller, Nancy, Kumar, Rakesh, Patel, Sandip Pravin
Publicado 2023

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study

por Qin, Yong, Petaccia de Macedo, Mariana, Reuben, Alexandre, Forget, Marie-Andrée, Haymaker, Cara, Bernatchez, Chantale, Spencer, Christine N., Gopalakrishnan, Vancheswaran, Reddy, Sujan, Cooper, Zachary A., Fulbright, Orenthial J., Ramachandran, Renjith, Wahl, Arely, Flores, Esteban, Thorsen, Shawne T., Tavera, Rene J., Conrad, Claudius, Williams, Michelle D., Tetzlaff, Michael T., Wang, Wei-Lien, Gombos, Dan S., Esmaeli, Bita, Amaria, Rodabe N., Hwu, Patrick, Wargo, Jennifer A., Lazar, Alexander J., Patel, Sapna P.
Publicado 2017